increase font size
Head OfficeClinuvel Pharmaceuticals Limited, Tel: +61 3 9660 4900 |
Swiss OfficeNeuhofstrasse 3D Tel: +41 41 767 4545 |
US Office30 Broad Street Tel: +1 646 480 4810 |
Clinuvel receives a large number of inquiries every day. For a list of frequently asked questions, including information on projected release dates and trial participation please click here.
For more information on Clinuvel’s program for SCENESSE® in vitiligo, please go to http://www.clinuvel.com/vitiligo.
“Basal cell carcinoma skin cancer is the most common form of skin cancer”. It’s a common claim and one which is undoubtedly true –...
Read More
Earlier today we announced that two health insurers in Switzerland had agreed to reimburse SCENESSE® (afamelanotide) for the rare disease...
Read More
In a letter published this week in the British Journal of Medicine three dermatologists have highlighted the potential risks posed by the...
Read More
Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin. Though it affects around 45 million people worldwide,... Watch now |
On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes ab... Watch now |
Following Clinuvel's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medic... Watch now |
The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an... Read more |
